Initiatives among Authorities to Improve the Quality and Efficiency of Prescribing and the Implications

Godman B^1,2,3*, Acurcio FA^4,5, Guerra Júnior AA⁵, Alvarez-Madrazo S², Faridah Aryani MY⁶, Bishop I⁷, Campbell S⁸, Eriksson I⁹, Finlayson AE¹⁰, Fürst J¹¹, Garuoliene K¹², Hussain S¹³, Kalaba M¹⁴, Jayathissa S¹⁵, Abdol Malek AA¹⁶, Małecka-Massalska T¹⁷, Mansor Manan M¹⁸, Martin A¹⁹, Pedersen H²⁰, Sović Brkičić L²¹, Smoleń A²², Truter I²³, Wale J²⁴ and Gustafsson LL¹

¹Division of Clinical Pharmacology, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden, E-mail: Acurcio12@gamil.com

²Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, Glasgow, UK, E-mail: Acurcio12@gamil.com

³National Institute for Science and Technology on Innovation on Neglected Diseases, Centre for Technological Development in Health, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, E-mail: Acurcio12@gamil.com

⁴Medical College, Federal University of Minas Gerais (UFMG), Av. Alfredo Balena, 190, 7th floor, CEP 30130-100, Belo Horizonte, MG, Brazil, E-mail: Acurcio12@gamil.com

⁵Pharmacy College, Federal University of Minas Gerais (UFMG), Av. Antônio Carlos, 6627, sl 1048, CEP 31270-901, Belo Horizonte, MG, Brazil, E-mail: Acurcio12@gamil.com

⁶Pharmaceutical Services Division, Ministry of Health, Kuala Lumpur, Malaysia, E-mail: Acurcio12@gamil.com

⁷Public Health and Intelligence Business Unit, NHS National Services Scotland, Edinburgh, UK, E-mail: Acurcio12@gamil.com

⁸Centre for Primary Care, Institute of Population Health, University of Manchester, UK, E-mail: Acurcio12@gamil.com

⁹Public Healthcare Services Committee Administration, Stockholm County Council, Stockholm, Sweden, E-mail: Acurcio12@gamil.com

¹⁰Doll Fellow, Green-Templeton College, Oxford University and Academic Clinical Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK, E-mail: Acurcio12@gamil.com

¹¹Health Insurance Institute, Ljubljana, Slovenia, E-mail: Acurcio12@gamil.com

¹²Medicines Reimbursement Department, National Health Insurance Fund, Vilnius, Lithuania, E-mail: Acurcio12@gamil.com

¹³National Institute of Health, Islamabad, Pakistan, E-mail: Acurcio12@gamil.com

¹⁴Republic Fund for Health Insurance, Belgrade, Serbia, E-mail: Acurcio12@gamil.com

¹⁵Department of Medicine, Hutt Valley DHB, Lower Hutt, Wellington, New Zealand, E-mail: Acurcio12@gamil.com

¹⁶Hospital Tuanku Ja’afar, Seremban, Malaysia, E-mail: Acurcio12@gamil.com

¹⁷Physiology Department, Medical University of Lublin, Radziwillowska Street 11, 20-080 Lublin, Poland, E-mail: Acurcio12@gamil.com

¹⁸UiTM Puncak Alam, Selangor, Malaysia, E-mail: Acurcio12@gamil.com

¹⁹NHS North West Commissioning Support Unit, Salford, Manchester M6 5FW, UK, E-mail: Acurcio12@gamil.com

²⁰Health Technologies and Pharmaceuticals, Division of Health Systems and Public Health, WHO Regional Office for Europe, Copenhagen, Denmark, E-mail: Acurcio12@gamil.com

²¹Croatian Health Insurance Fund, Branimirova 37, Zagreb, Croatia, E-mail: Acurcio12@gamil.com

²²Department of Epidemiology, Medical University of Lublin, 1 Chodzki St, 20-093 Lublin, Poland, E-mail: Acurcio12@gamil.com

²³Drug Utilization Research Unit (DURU), Department of Pharmacy, Nelson Mandela Metropolitan University (NMMU), Port Elizabeth, 6031, South Africa, E-mail: Acurcio12@gamil.com

²⁴Independent consumer advocate, Victoria, Melbourne, Australia, E-mail: Acurcio12@gamil.com

^*Corresponding Author: Godman B, Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, SE-141 86, Stockholm, Sweden